Oxidative Stress in Serum and Peripheral Blood Leukocytes in Patients with Different Disease Courses of Multiple Sclerosis

Overview

Journal J Neurol

Specialty Neurology

Date 2005 Nov 12

PMID 16283096

Citations 28

Authors

Marcus Koch

Geeta S M Ramsaransing

Alexander V Arutjunyan

Michael Stepanov

Albert Teelken

Dorothea J Heersema

Jacques De Keyser

Affiliations

Soon will be listed here.

Abstract

Background: The role of oxidative stress in patients with multiple sclerosis (MS) is poorly understood.

Objective: To investigate oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of MS.

Methods: Diene conjugate (DC) levels (a measure of lipid peroxidation), total antioxidative activity (AOA) and total antiradical activity (ARA) were measured in serum and peripheral blood leukocytes from 30 patients with benign relapsing remitting MS (BMS), 27 with secondary progressive MS (SPMS), 29 with primary progressive MS (PPMS), and 30 healthy controls. All MS patients were in a clinically stable phase.

Results: Serum DC levels were elevated in patients with BMS (p <0.05), SPMS (p <0.01) and PPMS (p <0.001). Serum total AOA and ARA were not different between MS patients and controls. Compared to controls, leukocyte DC levels were not different in each MS subgroup, but total ARA was elevated. There was a strong correlation, both in controls and MS patients, between leukocyte DC levels and leukocyte total ARA (p <0.0001) and leukocyte total AOA (p <0.0001).

Conclusion: Oxidative stress occurs in progressive as well as benign MS. The finding that cells withstand oxidative stress, due to upregulated cellular antioxidant defence mechanisms, suggests that reactive oxygen species (ROS) formation in MS is not necessarily deleterious.

Citing Articles

The benefits of photobiomodulation in animal models of multiple sclerosis: a systematic review and meta-analysis.

Ahmed Z Front Neurol. 2024; 15:1482096.

PMID: 39502387 PMC: 11534619. DOI: 10.3389/fneur.2024.1482096.

Cerebrovascular hemodynamics association with brain structure and function in Multiple Sclerosis.

Duque C, Mahinrad S, Sedaghat S, Higgins J, Milstead A, Sargento-Freitas J Mult Scler Relat Disord. 2024; 91:105882.

PMID: 39276598 PMC: 11835024. DOI: 10.1016/j.msard.2024.105882.

Oxidative Stress Markers in Multiple Sclerosis.

Jimenez-Jimenez F, Alonso-Navarro H, Salgado-Camara P, Garcia-Martin E, Agundez J Int J Mol Sci. 2024; 25(12).

PMID: 38927996 PMC: 11203935. DOI: 10.3390/ijms25126289.

Decreased Cerebrospinal Fluid Antioxidative Capacity Is Related to Disease Severity and Progression in Early Multiple Sclerosis.

Voortman M, Damulina A, Pirpamer L, Pinter D, Pichler A, Enzinger C Biomolecules. 2021; 11(9).

PMID: 34572477 PMC: 8472420. DOI: 10.3390/biom11091264.

Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review.

Salari N, Rasoulpoor S, Hosseinian-Far A, Razazian N, Mansouri K, Mohammadi M Neurol Sci. 2020; 42(2):491-500.

PMID: 33095366 DOI: 10.1007/s10072-020-04842-3.

References

Chen X, Kunsch C . Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr Pharm Des. 2004; 10(8):879-91. DOI: 10.2174/1381612043452901. View

Ischiropoulos H, Beckman J . Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J Clin Invest. 2003; 111(2):163-9. PMC: 151889. DOI: 10.1172/JCI17638. View

Choo L, Jackson M, Halliday W, Mantsch H . Infrared spectroscopic characterisation of multiple sclerosis plaques in the human central nervous system. Biochim Biophys Acta. 1993; 1182(3):333-7. DOI: 10.1016/0925-4439(93)90078-f. View

Andrews H, Nichols P, Bates D, Turnbull D . Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis. Med Hypotheses. 2005; 64(4):669-77. DOI: 10.1016/j.mehy.2004.09.001. View

De Keyser J, Zeinstra E, Mostert J, Wilczak N . Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis. Trends Pharmacol Sci. 2004; 25(2):67-71. DOI: 10.1016/j.tips.2003.12.002. View

Shull S, Heintz N, Periasamy M, Manohar M, Janssen Y, Marsh J . Differential regulation of antioxidant enzymes in response to oxidants. J Biol Chem. 1991; 266(36):24398-403. View

Smith K, Lassmann H . The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2003; 1(4):232-41. DOI: 10.1016/s1474-4422(02)00102-3. View

Clerch L, Massaro D . Tolerance of rats to hyperoxia. Lung antioxidant enzyme gene expression. J Clin Invest. 1993; 91(2):499-508. PMC: 287967. DOI: 10.1172/JCI116228. View

Kapoor R, Davies M, Blaker P, Hall S, Smith K . Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol. 2003; 53(2):174-80. DOI: 10.1002/ana.10443. View

10.

Toshniwal P, Zarling E . Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem Res. 1992; 17(2):205-7. DOI: 10.1007/BF00966801. View

11.

Kostiuk V, Potapovich A, LUNETS E . [Spectrophotometric evaluation of diene conjugates]. Vopr Med Khim. 1984; 30(4):125-7. View

12.

Browne S, Ferrante R, Beal M . Oxidative stress in Huntington's disease. Brain Pathol. 1999; 9(1):147-63. PMC: 8098260. DOI: 10.1111/j.1750-3639.1999.tb00216.x. View

13.

Davie C, Silver N, Barker G, Tofts P, Thompson A, McDonald W . Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?. J Neurol Neurosurg Psychiatry. 1999; 67(6):710-5. PMC: 1736689. DOI: 10.1136/jnnp.67.6.710. View

14.

Beal M, Hyman B, Koroshetz W . Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?. Trends Neurosci. 1993; 16(4):125-31. DOI: 10.1016/0166-2236(93)90117-5. View

15.

Kassiotis G, Kollias G . Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001; 193(4):427-34. PMC: 2195909. DOI: 10.1084/jem.193.4.427. View

16.

Andersen J . Oxidative stress in neurodegeneration: cause or consequence?. Nat Med. 2004; 10 Suppl:S18-25. DOI: 10.1038/nrn1434. View

17.

Kosov M, Prokopenko V, Oparina T, Evsiukova I, Arutiunian A . [Free radical oxidation and antioxidant system in healthy full-term newborns]. Fiziol Cheloveka. 2001; 27(3):133-6. View

18.

Falini A, Calabrese G, Filippi M, Origgi D, Lipari S, Colombo B . Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. AJNR Am J Neuroradiol. 1998; 19(2):223-9. PMC: 8338171. View

19.

Burmistrov S, Oparina T, Prokopenko V, Arutiunian A . [Antioxidant activity of the blood serum in pregnant and nonpregnant women: comparison of various detection methods]. Klin Lab Diagn. 1998; (11):14-7. View

20.

Calabrese V, Scapagnini G, Stella A, Bates T, Clark J . Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res. 2001; 26(6):739-64. DOI: 10.1023/a:1010955807739. View